ImageneBio, Inc. (IMA)

ImageneBio, Inc. is a clinical-stage biotechnology company. It was created through the combination of Ikena Oncology with Inmagene Biopharmaceuticals, a developer of immunology therapies, and it continues as the Nasdaq-listed company.

The company focuses on developing treatments for immunological and inflammatory diseases. Its lead program is an antibody targeting the OX40 pathway that is being studied in conditions such as atopic dermatitis and other inflammatory skin disorders.

As a clinical-stage company, ImageneBio does not yet have approved products, and its activities center on running clinical trials and advancing its pipeline toward regulatory milestones.